Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade. However, resistance to sorafenib limits patient response and presents a major hurdle during HCC treatment. Lenvatinib has been a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Tingting, Iwama, Hisakazu, Fujita, Koji, Kobara, Hideki, Nishiyama, Noriko, Fujihara, Shintaro, Goda, Yasuhiro, Yoneyama, Hirohito, Morishita, Asahiro, Tani, Joji, Yamada, Mari, Nakahara, Mai, Takuma, Kei, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657692/
https://www.ncbi.nlm.nih.gov/pubmed/34884875
http://dx.doi.org/10.3390/ijms222313071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657692/
https://www.ncbi.nlm.nih.gov/pubmed/34884875
http://dx.doi.org/10.3390/ijms222313071

Ejemplares similares